NCT06477484 · RECRUITING
Blood Biomarkers for Screening of Alzheimer's Disease
This observational study is testing whether certain proteins measured in a blood sample can reliably identify Alzheimer's disease early. Researchers are measuring six biomarkers including amyloid, tau, and inflammation-related proteins in people with Alzheimer's, mild cognitive impairment, and healthy individuals. No drugs or treatments are involved. The phase is unspecified, meaning this is likely early-stage research aimed at validating a screening tool rather than testing a therapy.
You may qualify if
- Age ≥ 50 years;
- AD (meets the 2011 NIA-AA AD diagnostic criteria), or MCI (meets the 2004 Peterson MCI diagnostic criteria), or cognitively normal subjects;
- Signed informed consent form.
You're excluded if
- The presence of other disorders that can cause cognitive impairment;
- Unable to cooperate with the completion of cognitive assessment;
- Refusal to draw blood.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2024-06-27